Arbutus Biopharma received approximately $178 million on July 8, 2026, as its share of a $950 million noncontingent settlement payment from Moderna to resolve global patent infringement litigation. The company terminated its RSV Agreement with Genevant Sciences, receiving a $1.0 million termination fee. Arbutus filed three international lawsuits against Pfizer/BioNTech to enforce lipid nanoparticle technology patents. Additionally, the company announced plans to return up to $230 million to shareholders through share repurchases starting in Q3 2026, following an expected dividend from Genevant's parent. The Board approved litigation-related bonuses for CEO Lindsay Androski and CFO Tuan Nguyen. Arbutus Biopharma is a clinical-stage biopharmaceutical company focused on infectious diseases.